Regenxbio and Nippon Shinyaku forge $810m gene therapy deal
Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get up to $700m in development, regulatory, and sales milestones.
Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get up to $700m in development, regulatory, and sales milestones.
What's Your Reaction?
